In 2006, the first association between PDE mutations and ACT, using a genome-wide association (GWA) study approach, was identified in patients with CS with PPNAD but without GNAS or PRKAR1A mutations (12). This evidence concerns the gene PRKAR1A and primary pigmented nodular adrenocortical disease.